<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:media="http://search.yahoo.com/mrss/" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" version="2.0">
    <channel>
        <title>Molecular Medicine</title>
        <description>Molecular Medicine publishes original research articles and expert commentaries on emerging concepts in the interdisciplinary field of molecular medicine.
Considered the vanguard of the new millennium in which science truly complements the art of medicine, Molecular Medicine strives to understand the molecules key to normal body functioning and the pathogenesis of disease, and based on that knowledge, to design specific molecular tools for diagnosis, treatment and prevention.
A nonprofit journal organized and peer-reviewed by expert scientists and editors, Molecular Medicine is committed to:
• providing a venue where rigor and scholarship reign,
• promoting and advancing scientific discourse, and
• imparting a common language and understanding among diverse clinical groups, from allergists to virologists and everyone in between.
Like the field, Molecular Medicine the journal continues to grow as it scales the heights of modern biomedical science. It has captured the imagination of many of the best basic science and clinical investigators. Pick up an issue today and see for yourself!</description>
        <link>http://www.molmed.org</link>
        <category>Science &amp; Medicine</category>
        <copyright>2008 Molecular Medicine</copyright>
        <lastBuildDate>Wed, 18 Aug 2010 09:38:11 -0400</lastBuildDate>
        <managingEditor>mpuerta@NSHS.edu</managingEditor>
        <pubDate>Wed, 18 Aug 2010 09:37:37 -0400</pubDate>
        <webMaster>kstroud@optonline.net</webMaster>
        <generator>FeedForAll Mac v2.1 (2.1.0.2); http://www.FeedForAll.com/</generator>
        <image>
            <url>http://www.molmed.org/images/MolMedCover7_8_10.jpg</url>
            <title>Molecular Medicine</title>
            <link>http://www.molmed.org</link>
            <description>Insight into the Cellular and Molecular Basis of Disease</description>
            <width>111</width>
            <height>144</height>
        </image>
        <item>
            <title>Chewing the Fat: Insulin Signaling In Type 2 Diabetes</title>
            <description>Type 2 diabetes (T2D) is strongly associated with obesity and is characterized by early and marked insulin resistance in adipose tissue. Consequently, T2D is associated with disrupted cellular metabolism. While insulin resistance in T2D is due to defects in signaling, the details remain largely unknown. Target of rapamycin (TOR) plays a key role in cellular metabolism control, cell growth and tolerance to starvation. In mammals, TOR forms a complex with the protein raptor (mTORC1). Öst &lt;i&gt;et al&lt;/i&gt;. further investigated the function of mTORC1 in subjects with type 2 diabetes and a BMI greater than 27. Results in adipocytes from obese patients show insulin-activated mTORC1 is attenuated, autophagic activity is increased, and mitochondrial function is impaired. These findings further our understanding of insulin resistance mechanis</description>
            <link>http://www.molmed.org/content/2010/7_8_10/10_23_Ost.pdf</link>
            <guid isPermaLink="false">6D4B89D4-916C-11DC-909A-0014510BD93E-17496-0000048FE4895858-FFA</guid>
            <pubDate>Wed, 18 Aug 2010 09:17:33 -0400</pubDate>
        </item>

        <item>
            <title>Improving The Success Of Pancreas Transplants</title>
            <description>Patients with type 1 diabetes face the prospect of complications such as nephropathy, neuropathy, retinopathy and cardiovascular disease. A successful pancreas transplant provides almost normal glucose homeostasis, but patients require lifelong immunosuppressive medication. Wee &lt;i&gt;et al.&lt;/i&gt; investigated the effect of the T-cell apoptosis compound tautomycetin (TMC) on rat islet transplantation both alone and in combination with cyclosporine A (CsA). They demonstrate that TMC inhibits T-cell proliferation without affecting islet or splenocyte viability. The authors also found that islet allograft survival could be prolonged through a combination of TMC and subtherapeutic doses of CsA. Furthermore, the same experimental doses of either immunosuppressive agent alone did not result in any beneficial effect on islet allografts. This novel combination of known agents may lead to greater long-term success of pancreas transplants in those suffering with diabe</description>
            <link>http://www.molmed.org/content/2010/7_8_10/09_99_Wee.pdf</link>
            <guid isPermaLink="false">CD9B8AE6-A9BA-11DD-860A-0014510BD93E-733-0000002C57448DCD-FFA</guid>
            <pubDate>Wed, 18 Aug 2010 09:23:20 -0400</pubDate>
        </item>

        <item>
            <title>View Articles in the July-August 2010 Issue of Molecular Medicine</title>
            <description></description>
            <link>http://www.molmed.org/content/2010/7_8_10.htm</link>
            <guid isPermaLink="false">F4FE4178-B947-11DC-AB6F-0014510BD93E-5990-0000015FEE23FAC9-FFA</guid>
            <pubDate>Wed, 18 Aug 2010 09:33:37 -0400</pubDate>
        </item>

        <item>
            <title>Papers in Press - Read new papers prior to publication.</title>
            <description></description>
            <link>http://www.molmed.org</link>
            <guid isPermaLink="false">E83EBF4E-8701-11DC-B50B-0014510BD93E-3049-0000012299B8F2DB-FFA</guid>
            <pubDate>Fri, 06 Aug 2010 09:05:32 -0400</pubDate>
        </item>

    </channel>
</rss>
